178 related articles for article (PubMed ID: 38111587)
1. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract][Full Text] [Related]
2. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
3. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
4. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated endothelial cell prognostic risk model and tumor immune environment modulation in liver cancer based on single-cell and bulk RNA sequencing: Experimental verification.
Yang D; Kuang T; Zhou Y; Su Y; Shen J; Yu B; Zhao K; Ding Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110870. PubMed ID: 37690233
[TBL] [Abstract][Full Text] [Related]
6. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
7. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
8. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
9. Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.
Liu J; Deng Y; Liu Z; Li X; Zhang M; Yu X; Liu T; Chen K; Li Z
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512096
[No Abstract] [Full Text] [Related]
10. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
12. Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC.
Wu H; Feng J; Zhong W; Zouxu X; Xiong Z; Huang W; Zhang C; Wang X; Yi J
Front Immunol; 2023; 14():1151800. PubMed ID: 36999020
[TBL] [Abstract][Full Text] [Related]
13. Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer.
Shi Y; Huang X; Du Z; Tan J
Math Biosci Eng; 2022 Apr; 19(6):5793-5812. PubMed ID: 35603379
[TBL] [Abstract][Full Text] [Related]
14. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy.
Zhu Y; Tao LF; Liu JY; Wang YX; Huang H; Jiang YN; Qian WF
Cancer Med; 2023 Jul; 12(14):15704-15719. PubMed ID: 37306188
[TBL] [Abstract][Full Text] [Related]
15. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
16. Development of an immune-related prognostic biomarker for triple-negative breast cancer.
Zhang Y; Wang Q; Yang WK; Wang YS; Zhou Q; Lin J; Wei XX; Liang T; Liu T; Fan WT; Liang L; Xu YN
Ann Med; 2022 Dec; 54(1):1212-1220. PubMed ID: 35481432
[No Abstract] [Full Text] [Related]
17. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
18. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
19. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer.
Sun X; Zhang T
Front Genet; 2022; 13():1067254. PubMed ID: 36452159
[No Abstract] [Full Text] [Related]
20. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
